ArticleOncoimmunology
Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04806178 (Systemic Immunological Response of Bladder Cancer Patients Under Bacillus Calmette Guérin Treatment), which is not on this map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Systemic Immunological Response of Bladder Cancer Patients Under Bacillus Calmette Guérin Treatment
Who cites it
28 citing papers in PubMed, 36 citations in OpenAlex.
- Intradermal priming to intravesical Bacillus Calmette-Guérin in non-muscle invasive bladder cancer: A translational research and phase I clinical trial.Oncology research · 2025Trial
- Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study.Journal for immunotherapy of cancer · 2021Trial
- Unveiling the Paradoxical Tumor-Suppressive Role of CCL2/CCR2 in Bladder Cancer: A Novel Immunotherapeutic Strategy.Cancers · 2026Article
- A Double-Humanized Murine Model in Bladder Cancer: A Novel Preclinical Model for Cancer Immunology Research.Cancer medicine · 2025Article
- BCG therapy in bladder cancer and its tumor microenvironment interactions.Clinical microbiology reviews · 2025Review
- Targeting tumor‑associated macrophages: Critical players in tumor progression and therapeutic strategies (Review).International journal of oncology · 2024Review
- Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies.Cancer immunology research · 2024Review
- Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.Journal of cancer immunology · 2024Article
- Article
- Review
- Article
- Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer.Cancer immunology, immunotherapy : CII · 2023Article
- The generation, activation, and polarization of monocyte-derived macrophages in human malignancies.Frontiers in immunology · 2023Review
- Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment.Nature communications · 2022Article
- Macrophages as tools and targets in cancer therapy.Nature reviews. Drug discovery · 2022Review
- Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity.International journal of molecular sciences · 2022Article
- Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective.Cancers · 2022Review
- Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils.Frontiers in oncology · 2022Review
- Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.Vaccine · 2021Review
- γδ T Cells Support Antigen-Specific αβ T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer.Cancer immunology research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Niannian JiDepartment of Urology, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
Neelam MukherjeeDepartment of Urology, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
Edwin E MoralesDepartment of Urology, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
Maggie E TomasiniDepartment of Urology, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
Vincent HurezDepartment of Medicine/Hematology & Medical Oncology, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
Tyler J CurielDepartment of Medicine/Hematology & Medical Oncology, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
Getahun AbateDepartment of Internal Medicine, Division of Infectious Diseases, Allergy and Immunology, Saint Louis University Edward A. Doisy Research Center, .St. Louis, MO, USA.
Dan F HoftDepartment of Internal Medicine, Division of Infectious Diseases, Allergy and Immunology, Saint Louis University Edward A. Doisy Research Center, .St. Louis, MO, USA.
Xiang-Ru ZhaoDepartment of Medicine/Hematology & Medical Oncology, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
Jon GelfondDepartment of Epidemiology and Biostatistics, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
Sourindra MaitiPediatrics, M.D. Anderson Cancer Center, Houston, TX, USA.
Laurence J N CooperPediatrics, M.D. Anderson Cancer Center, Houston, TX, USA.
Robert S SvatekDepartment of Urology, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
The University of Texas Health Science Center at San Antonio · USSaint Louis University · USThe University of Texas MD Anderson Cancer Center · US
Funding
San Antonio OAIC - Research Education Component (REC)P30AG044271 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Adam Salmon · 2015 to 2026
$14.1MRole of gammadelta T Cells in Vaccine-Induced ImmunityR01AI048391 · NIAID · SAINT LOUIS UNIVERSITY · PI HOFT, DANIEL F. · 2002 to 2019
$6.1MImproving immunotherapy in bladder cancer by targeting immune dysfunctionK23CA178204 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SVATEK, ROBERT SCOTT · 2014 to 2017
$674kNCI NIH HHS K23 CA178204NIAID NIH HHS R01 AI048391NIA NIH HHS P30 AG044271
Abstract
PubMed holds no abstract for this paper.
Indexed as
BCGbladder cancerclinical trialPrimingvaccine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04806178ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.